Loading...

China Biologic Products Holdings

DB:2CH
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2CH
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
2CH Share Price and Events
7 Day Returns
-0.2%
DB:2CH
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:2CH
-10.2%
DE Biotechs
-6%
DE Market
2CH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
China Biologic Products Holdings (2CH) -0.2% 10.5% 20.5% - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 2CH.
  • No trading data on 2CH.
Price Volatility
Industry
5yr Volatility vs Market

2CH Value

 Is China Biologic Products Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of China Biologic Products Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for China Biologic Products Holdings.

DB:2CH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2CH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 25%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:2CH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for China Biologic Products Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:2CH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 122.65 Analyst x2 113.59
2020 121.10 Analyst x2 103.87
2021 120.11 Est @ -0.82% 95.41
2022 119.50 Est @ -0.51% 87.91
2023 119.16 Est @ -0.29% 81.19
2024 119.00 Est @ -0.13% 75.09
2025 118.97 Est @ -0.02% 69.53
2026 119.04 Est @ 0.05% 64.43
2027 119.16 Est @ 0.1% 59.73
2028 119.33 Est @ 0.14% 55.40
Present value of next 10 years cash flows $806.15
DB:2CH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $119.33 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$1,543.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,543.68 ÷ (1 + 7.98%)10
$716.63
DB:2CH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $806.15 + $716.63
$1,522.77
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,522.77 / 39.36
$38.69
DB:2CH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2CH represents 0.8814x of NasdaqGS:CBPO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8814x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 38.69 x 0.8814
€34.10
Value per share (EUR) From above. €34.10
Current discount Discount to share price of €85.54
= -1 x (€85.54 - €34.10) / €34.10
-150.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of China Biologic Products Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for China Biologic Products Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are China Biologic Products Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2CH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $3.54
NasdaqGS:CBPO Share Price ** NasdaqGS (2019-04-18) in USD $97.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of China Biologic Products Holdings.

DB:2CH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CBPO Share Price ÷ EPS (both in USD)

= 97.05 ÷ 3.54

27.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Biologic Products Holdings is overvalued based on earnings compared to the Europe Biotechs industry average.
  • China Biologic Products Holdings is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does China Biologic Products Holdings's expected growth come at a high price?
Raw Data
DB:2CH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 27.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:2CH PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 27.41x ÷ 5%

5.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Biologic Products Holdings is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on China Biologic Products Holdings's assets?
Raw Data
DB:2CH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $43.75
NasdaqGS:CBPO Share Price * NasdaqGS (2019-04-18) in USD $97.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2CH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CBPO Share Price ÷ Book Value per Share (both in USD)

= 97.05 ÷ 43.75

2.22x

* Primary Listing of China Biologic Products Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Biologic Products Holdings is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess China Biologic Products Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. China Biologic Products Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2CH Future Performance

 How is China Biologic Products Holdings expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is China Biologic Products Holdings expected to grow at an attractive rate?
  • China Biologic Products Holdings's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • China Biologic Products Holdings's earnings growth is positive but not above the Germany market average.
  • China Biologic Products Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2CH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2CH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 5%
DB:2CH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 7.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2CH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2CH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 587 490 144 4
2020-12-31 524 153 129 7
2019-12-31 493 258 120 7
DB:2CH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 467 104 125
2018-09-30 442 101 66
2018-06-30 423 111 65
2018-03-31 391 112 67
2017-12-31 370 102 66
2017-09-30 358 109 111
2017-06-30 345 103 105
2017-03-31 347 112 105
2016-12-31 341 123 102
2016-09-30 332 124 99
2016-06-30 324 132 94
2016-03-31 312 117 90

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • China Biologic Products Holdings's earnings are expected to grow by 5% yearly, however this is not considered high growth (20% yearly).
  • China Biologic Products Holdings's revenue is expected to grow by 7.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2CH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from China Biologic Products Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 3.86 4.90 3.03 3.00
2020-12-31 3.64 4.75 2.79 5.00
2019-12-31 3.32 4.21 2.59 3.00
DB:2CH Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 3.54
2018-09-30 2.05
2018-06-30 2.14
2018-03-31 2.33
2017-12-31 2.40
2017-09-30 4.09
2017-06-30 3.88
2017-03-31 3.90
2016-12-31 3.79
2016-09-30 3.70
2016-06-30 3.54
2016-03-31 3.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • China Biologic Products Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess China Biologic Products Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
China Biologic Products Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2CH Past Performance

  How has China Biologic Products Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare China Biologic Products Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • China Biologic Products Holdings's year on year earnings growth rate has been positive over the past 5 years.
  • China Biologic Products Holdings's 1-year earnings growth exceeds its 5-year average (90.1% vs 7.5%)
  • China Biologic Products Holdings's earnings growth has exceeded the Europe Biotechs industry average in the past year (90.1% vs 18.2%).
Earnings and Revenue History
China Biologic Products Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from China Biologic Products Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 466.88 124.98 164.39 9.52
2018-09-30 442.06 66.32 170.60 8.37
2018-06-30 422.52 64.96 148.64 6.88
2018-03-31 391.42 67.35 121.55 6.86
2017-12-31 370.41 65.75 100.63 6.50
2017-09-30 357.93 111.35 84.52 8.27
2017-06-30 344.89 105.28 74.95 7.91
2017-03-31 347.03 105.25 72.71 7.28
2016-12-31 341.17 101.79 66.20 7.02
2016-09-30 331.82 98.89 62.92 5.48
2016-06-30 324.04 93.69 58.99 6.03
2016-03-31 311.69 89.86 54.12 5.78
2015-12-31 296.46 86.97 51.36 6.02
2015-09-30 286.16 83.65 47.46 3.45
2015-06-30 276.33 81.07 43.43 3.64
2015-03-31 257.34 74.35 43.14 4.43
2014-12-31 243.25 69.71 42.84 4.16
2014-09-30 227.86 65.84 43.21 6.12
2014-06-30 212.09 60.67 44.83 5.39
2014-03-31 205.59 57.32 45.69 4.38
2013-12-31 203.36 54.15 46.72 4.22
2013-09-30 194.76 51.23 42.84 3.56
2013-06-30 194.73 50.28 46.22 3.14
2013-03-31 191.62 47.04 47.01 3.24
2012-12-31 184.81 45.15 48.46 3.03
2012-09-30 186.47 44.03 52.90 3.82
2012-06-30 174.65 21.07 49.57 3.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • China Biologic Products Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • China Biologic Products Holdings used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • China Biologic Products Holdings's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess China Biologic Products Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
China Biologic Products Holdings has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2CH Health

 How is China Biologic Products Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up China Biologic Products Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • China Biologic Products Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • China Biologic Products Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of China Biologic Products Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • China Biologic Products Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from China Biologic Products Holdings Company Filings, last reported 3 months ago.

DB:2CH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,844.70 0.00 952.41
2018-09-30 1,807.29 0.00 953.20
2018-06-30 1,233.51 0.00 366.17
2018-03-31 1,231.78 0.00 366.64
2017-12-31 664.32 0.00 242.23
2017-09-30 665.07 0.00 216.45
2017-06-30 614.92 14.47 223.24
2017-03-31 560.86 10.81 197.36
2016-12-31 521.14 0.00 183.77
2016-09-30 566.96 0.00 203.20
2016-06-30 535.52 0.00 204.03
2016-03-31 504.19 0.00 180.12
2015-12-31 466.96 2.24 182.97
2015-09-30 449.68 0.00 181.48
2015-06-30 425.45 0.00 178.84
2015-03-31 306.48 66.30 85.99
2014-12-31 275.26 100.27 80.82
2014-09-30 258.39 118.07 74.58
2014-06-30 286.47 107.24 103.22
2014-03-31 255.99 107.23 77.55
2013-12-31 303.97 42.21 150.75
2013-09-30 294.72 37.26 131.50
2013-06-30 303.78 7.22 147.26
2013-03-31 277.82 7.11 138.71
2012-12-31 257.42 10.25 129.61
2012-09-30 247.39 13.39 134.45
2012-06-30 227.80 2.29 105.83
  • China Biologic Products Holdings has no debt.
  • China Biologic Products Holdings has no debt compared to 5 years ago when it was 14.1%.
  • China Biologic Products Holdings has no debt, it does not need to be covered by operating cash flow.
  • China Biologic Products Holdings has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess China Biologic Products Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. China Biologic Products Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2CH Dividends

 What is China Biologic Products Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from China Biologic Products Holdings dividends. Estimated to be 0% next year.
If you bought €2,000 of China Biologic Products Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate China Biologic Products Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate China Biologic Products Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2CH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2CH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as China Biologic Products Holdings has not reported any payouts.
  • Unable to verify if China Biologic Products Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of China Biologic Products Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as China Biologic Products Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of China Biologic Products Holdings's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess China Biologic Products Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can China Biologic Products Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. China Biologic Products Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2CH Management

 What is the CEO of China Biologic Products Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bing Li
COMPENSATION $179,865
AGE 50
TENURE AS CEO 0.7 years
CEO Bio

Dr. Bing Li has been Chief Executive Officer of China Biologic Products Holdings Inc. since August 13, 2018. Dr. Li served as Vice President of Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. since May 29, 2014 until March 2, 2016 and served as its General Manager of International Business Division until March 2, 2016. Dr. Li served as Managing Director of Fosun Group, a Chinese international conglomerate and investment company, from March 2016 to December 2017. Dr. Li has been an Advisor at Warburg Pincus Asia LLC since June 2010. Dr. Li served as an executive director of Warburg Pincus, an American private equity firm, from June 2010 to May 2014. In this capacity Dr. Li advises on potential investment evaluation and portfolio management in the healthcare space. Prior to joining Warburg Pincus Asia LLC, Dr. Li served from November 2007 to June 2010 as the General Manager of Enterprise Business and Business Development at GlaxoSmithKline China/Hong Kong and from August 2006 to October 2007, as the Commercial Development Director at GlaxoSmithKline China/Hong Kong. Prior to that, Dr. Li served from April 1999 to August 2006 in various positions with Eli Lilly and Company in the United States, including Manager of China/India strategy, Manager of Global New Product Planning for Drug Delivery System and Consultant to Biotechnology Strategy Group. While at GlaxoSmithKline, Dr. Li led efforts in creating the brand generics business and other new commercial models. Dr. Li has been a Director of China Biologic Products Holdings, Inc. since July 25, 2018. Dr. Li served as a Director of China Biologic Products, Inc. from February 27, 2011 to May 4, 2014. Dr. Li served as a Director of Shenzhen GSK NB. Dr. Li holds a Master of Business Administration and Master of Engineering Management from the Kellogg Graduate School of Management, Northwestern University and a PhD in Cell and Molecular Biology from the University of Rochester and a Bachelor of Science in Biophysics from Fudan University.

CEO Compensation
  • Bing's compensation has been consistent with company performance over the past year.
  • Insufficient data for Bing to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the China Biologic Products Holdings management team in years:

6.7
Average Tenure
50.5
Average Age
  • The average tenure for the China Biologic Products Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ming Yang

TITLE
Chief Financial Officer
AGE
46
TENURE
6.7 yrs

Ming Yin

TITLE
Senior Vice President
AGE
40
TENURE
6.7 yrs

Zhijing Liu

TITLE
Corporate Vice President
AGE
64
TENURE
6.7 yrs

Gang Yang

TITLE
Corporate VP & GM of Guizhou Taibang
AGE
53
TENURE
9.3 yrs

Bing Li

TITLE
CEO & Director
COMPENSATION
$180K
AGE
50
TENURE
0.7 yrs

Homer He

TITLE
Chief Business Officer
AGE
51
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the China Biologic Products Holdings board of directors in years:

1.3
Average Tenure
55
Average Age
  • The average tenure for the China Biologic Products Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joseph Chow

TITLE
Chairman
AGE
56
TENURE
0.2 yrs

Bing Li

TITLE
CEO & Director
COMPENSATION
$180K
AGE
50
TENURE
0.8 yrs

Sean Shao

TITLE
Independent Director
AGE
61
TENURE
10.8 yrs

Ken Lu

TITLE
Independent Director
AGE
56
TENURE
7.1 yrs

Qi Ning

TITLE
Independent Director
AGE
54
TENURE
0.8 yrs

David Li

TITLE
Director
AGE
50
TENURE
5.4 yrs

Yue’e Zhang

TITLE
Director
AGE
55
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Mar 19 Buy Beachhead Holdings Limited Company 04. Feb 19 08. Mar 19 394,007 €72.86 €28,707,141
04. Feb 19 Buy Beachhead Holdings Limited Company 08. Jan 19 01. Feb 19 451,679 €70.78 €28,953,799
08. Jan 19 Buy Beachhead Holdings Limited Company 17. Dec 18 07. Jan 19 419,872 €66.94 €27,478,269
18. Dec 18 Buy Beachhead Holdings Limited Company 19. Nov 18 14. Dec 18 427,664 €69.74 €29,826,271
19. Nov 18 Buy Beachhead Holdings Limited Company 06. Nov 18 16. Nov 18 550,262 €61.89 €34,053,437
31. Oct 18 Buy CITIC Capital Partners Company 29. Oct 18 30. Oct 18 770,000 €55.36 €42,626,800
16. Oct 18 Sell CITIC Capital Holdings Limited, Asset Management Arm Company 12. Oct 18 12. Oct 18 -2,680,863 €80.56 €-215,971,946
27. Aug 18 Buy CITIC Capital Holdings Limited, Asset Management Arm Company 24. Aug 18 24. Aug 18 1,000,000 €86.82 €86,824,450
18. Jun 18 Buy CITIC Capital Holdings Limited, Asset Management Arm Company 14. Jun 18 14. Jun 18 1,680,863 €40.14 €67,469,418
X
Management checks
We assess China Biologic Products Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. China Biologic Products Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2CH News

Simply Wall St News

2CH Company Info

Description

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People’s Republic of China.

Details
Name: China Biologic Products Holdings, Inc.
2CH
Exchange: DB
Founded:
$3,396,783,865
39,361,616
Website: http://www.chinabiologic.com
Address: China Biologic Products Holdings, Inc.
Jialong International Tower,
18th floor,
Beijing,
100125,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CBPO New Common Stock Nasdaq Global Select US USD 24. Jul 2017
DB 2CH New Common Stock Deutsche Boerse AG DE EUR 24. Jul 2017
LSE 0YWS New Common Stock London Stock Exchange GB USD 24. Jul 2017
BMV CBPO N New Common Stock Bolsa Mexicana de Valores MX MXN 24. Jul 2017
Number of employees
Current staff
Staff numbers
2,160
China Biologic Products Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.